Homo-and heteromeric complexes of KCNQ channel subunits are the molecular correlate of the M-current, a neuron-specific voltage-dependent K ϩ current with a well established role in control of neural excitability. We investigated the effect of KCNQ channel modulators on the activity of dopaminergic neurons in vitro and in vivo in the rat ventral mesencephalon. The firing of dopaminergic neurons recorded in mesencephalic slices was robustly inhibited in a concentration-dependent manner by the KCNQ channel opener N-(2-amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester (retigabine). The effect of retigabine persisted in the presence of tetrodotoxin and simultaneous blockade of GABA A receptors, smallconductance calcium-activated K ϩ (SK) channels, and hyperpolarization-activated (I h ) channels, and it was potently reversed by the KCNQ channel blocker 4-pyridinylmethyl-9(10H)-anthracenone (XE991), indicating a direct effect on KCNQ channels. Likewise, in vivo single unit recordings from dopaminergic neurons revealed a prominent reduction in spike activity after systemic administration of retigabine. Furthermore, retigabine inhibited dopamine synthesis and c-Fos expression in the striatum under basal conditions. Retigabine completely blocked the excitatory effect of dopamine D 2 autoreceptor antagonists. Again, the in vitro and in vivo effects of retigabine were completely reversed by preadministration of XE991. Dual immunocytochemistry revealed that KCNQ4 is the major KCNQ channel subunit expressed in all dopaminergic neurons in the mesolimbic and nigrostriatal pathways. Collectively, these observations indicate that retigabine negatively modulates dopaminergic neurotransmission, likely originating from stimulation of mesencephalic KCNQ4 channels.
phenyl) carbamic acid ethyl ester (retigabine) was the first KCNQ opener to be reported and is now in development as an antiepileptic compound (Blackburn-Munro et al., 2005) . In vitro, retigabine increases open probability of KCNQ channels by shifting the voltage dependence to more negative voltages (Tatulian et al., 2001) . This underlies the hyperpolarization and reduced firing frequency produced by the drug in various neuronal populations, including hippocampal and sympathetic neurons (Passmore et al., 2003; Yue and Yaari, 2004) . In these cell types, retigabine is thought to exert its inhibitory action by binding to KCNQ2/3 channels, because this KCNQ channel heteromer is expressed in significant quantities compared with other KCNQ channel subunit combinations (Cooper et al., 2001; Passmore et al., 2003) .
However, KCNQ channels also modulate the excitability of other cell types in the CNS. Thus, we have recently shown that retigabine profoundly inhibits haloperidol-induced c-Fos expression in the striatum (Mikkelsen, 2004 ), but we have not determined the site of action within the basal ganglia. In addition, flupirtine, a structural analog of retigabine, is reported to inhibit haloperidol-induced catalepsy (Schmidt et al., 1997) . Haloperidol-induced striatal c-Fos activation and catalepsy are hallmarks of acute blockade of dopamine (DA) D 2 autoreceptors , suggesting that retigabine interferes with DA neurotransmission. We therefore aimed at localizing the target area and the mechanism of action for retigabine's pronounced inhibitory effect on striatal excitability.
Using a range of immunohistochemical techniques, in vivo and in vitro electrophysiological recordings as well as in vivo microdialysis, we demonstrate that KCNQ channel stimulation profoundly inhibits neuronal excitability in mesencephalic neurons, which resulted in reduced DA activity in the striatum. This effect likely originates from stimulation of KCNQ4 channels located on DA neurons in the substantia nigra pars compacta and ventral tegmental area.
Materials and Methods
Animals. Unless stated specifically, adult male Wistar rats weighing 250 -300 g were used. All experiments were conducted in accordance with guidelines of the National Institute of Health (National Institutes of Health Publication 1985) and the Animal Experimentation Inspectorate, Ministry of Justice (Copenhagen, Denmark) .
Immunocytochemical Staining of KCNQ Subunits in the Ventral Tegmentum. For immunocytochemistry, the rats were anesthetized with mebumal (50 mg/ml; 3 ml/kg). Then, they were perfused with 0.1 M phosphate-buffered saline (PBS; pH 7.4), fixed in 4% paraformaldehyde-PBS for 10 min, and finally immersed in the fixative for 16 h at 4°C. The brains were cryoprotected in 20% sucrose-PBS for 48 h before sectioning. Forty-micrometer serial frontal sections were cut in series of six through the mesencephalon. Before the immunocytochemical steps, the sections were rinsed for 3 ϫ 10 min in 0.01 M PBS, for 10 min in 1% H 2 O 2 -PBS to block endogenous peroxidase activity, and for 30 min in 0.01 M PBS with 0.3% Triton X-100 (TX; Sigma-Aldrich, St. Louis, MO), 5% swine serum, and 1% bovine serum albumin (BSA) to block nonspecific binding sites. The sections were then incubated at 4°C for 24 h in antisera against KCNQ2 (1:1000) (Cooper et al., 2001) , KCNQ3 (1:1000) (Sigma-Aldrich), KCNQ4 (1:5000) (Kharkovets et al., 2000) , or KCNQ5 (1:1000) (Yus-Najera et al., 2003) . The antisera were diluted in 0.01 M PBS to which 0.3% Triton X-100 and 1% BSA were added.
After incubation in primary antiserum, immunoreactivity was detected by means of the avidin-biotin method using diaminobenzidine as chromogen according to previously described methods (Cooper et al., 2001) . In brief, the sections were washed in PBS with 0.1% TX and incubated for 60 min in biotinylated donkey anti-rabbit (The Jackson Laboratory, Bar Harbor, ME) diluted 1:800 in PBS with 1% BSA, washed again, and transferred to the avidin-biotin complex reaction (Vector Laboratories, Burlingame, CA) diluted 1:250 in PBS-TX. For KCNQ4, the tyramide amplification method was applied by subsequently incubating sections in biotinylated tyramide for 10 min (10 l/ml PBS ϩ 0.1% TX ϩ 0.005% H 2 O 2 ) and thereafter transferred to the avidin-biotin complex for additional staining.
Finally, after a careful wash, the sections were incubated in 0.05% diaminobenzidine (Sigma-Aldrich) with 0.05% H 2 O 2 in PBS buffer for 10 min and then washed twice in PBS buffer. The sections were mounted on gelatinized glass slides, dried, and coverslipped in Depex.
Double-Labeling Immunocytochemistry. For immunofluorescence colocalization studies, a mixture of a monoclonal antibody against tyrosine hydroxylase (TH; 1:5000; DiaSorin, Stillwater, MN) and anti-KCNQ4 (1:1000) was used. Subsequently, the sections were washed and incubated in a mixture of biotinylated donkey antirabbit (1:800) and Alexa Cy3-conjugated sheep anti-mouse (1:200; Invitrogen, Carlsbad, CA). The immunoreactions for KCNQ4 were completed using the tyramide-biotin procedure as described above with fluorescent avidin D (1:200; Vector Laboratories). The sections were mounted on cleaned slides using a fluorescence mounting medium (Dako Denmark A/S, Glostrup, Denmark) and visualized using confocal microscopy. Figures of representative photomicrographs were prepared using Adobe Photoshop CS (Adobe Systems, Mountain View, CA).
Extracellular Electrophysiological Recordings on Rat Midbrain Slices. The method used has been described previously (Seutin et al., 1990) . In brief, male Wistar rats (150 -200 g) were anesthetized with chloral hydrate (400 mg/kg i.p.; Sigma-Aldrich) and decapitated. The brain was rapidly removed and placed in icecold (ϳ4°C) artificial cerebrospinal fluid (ACSF) of the following composition: 130 mM NaCl, 3.5 mM KCl, 1.25 mM NaH 2 PO 4 , 1.25 mM MgSO 4 , 2 mM CaCl 2 , 10 mM glucose, and 24 mM NaHCO 3 , saturated with 95% O 2 and 5% CO 2 , pH 7.4. A block of tissue containing the midbrain was placed in a vibratome filled with icecold ACSF and cut in 400-m-thick horizontal slices. The mesencephalic slice was placed on a nylon mesh in a recording chamber (volume of 500 l). The tissue was held in position with an electron microscopy grid weighed down by short pieces of platinum wire. The slice was completely immersed in a continuously flowing (ϳ2 ml/ min), heated solution (34.5 Ϯ 0.5°C) of ACSF. The substantia nigra (SN) was identified by transillumination as a semilucent area rostral to the medial terminal nucleus of the accessory optic tract (Paxinos and Watson, 1986) . Additional experiments on the ventral tegmental area (VTA) were performed in the lateral part.
Extracellular single-cell recordings were made using glass microelectrodes filled with ACSF (resistance 5-10 M⍀). Action potentials were amplified and displayed on a Fluke digital oscilloscope (model PM 3370B; Fluke Corp., Everett, WA). They were selected with a window discriminator and counted with a digital counter. They were also fed to an analog digital interface (CED1401) connected to a computer. Data were collected and analyzed with the use of the Spike2 version 4 software (Cambridge Electronic Design, Cambridge, UK).
DA neurons in the substantia nigra pars compacta (SNc) recorded in vitro are characterized by long-duration, often triphasic action potentials (Ն2.5 ms) and a regular firing rate of 0.5 to 4 spikes/s. They are inhibited by nanomolar concentrations of the DA D 2 receptor agonists BHT-920, apomorphine, or quinpirole. In all experiments, a 5-min control period was taken to assess the stability of the cells. Drugs were then superfused using three-way taps so that the flow rate remained constant. Each concentration was superfused jpet.aspetjournals.org until equilibrium was obtained (duration usually 10 -15 min). For each concentration, the percentage of inhibition relative to the mean control period firing rate was calculated, and the concentration producing 50% inhibition (IC 50 ) was determined for each cell. When antagonists/channel blockers were tested, they were first superfused alone for 10 min before testing their ability to block the effect of agonists/channel openers.
Intracellular Recordings in Rat Midbrain Slices. The method for the rat midbrain slice preparation is similar to that described above for extracellular electrophysiological recordings. Intracellular recordings were made using glass microelectrodes filled with 2 M KCl (resistance 70 -150 M⍀). All recordings were made in the bridge balance mode, using an NPI SEC1L amplifier (NPI Electronic GmbH, Tamm, Germany). The accuracy of the bridge was checked throughout the experiments by examining the voltage deflection induced by a small (Ϯ50-pA) current injection. The potential of the extracellular medium was measured at the end of each experiment, and its absolute value was within 5 mV of that set to zero at the start. Membrane potentials and injected currents were recorded on a Gould TA240 chart recorder (Gould Instrument Systems Inc., Valley View, OH) and on a Fluke CombiScope oscilloscope (Fluke Corp.). The FlukeView software was used for off-line analysis. The characteristics of DA neurons recorded intracellularly have been described previously (Seutin et al., 1997) and include a slow (0.5-4-Hz) regular pacemaker-like firing, a significant SK channel-mediated afterhyperpolarization, and a robust I h channel-mediated current.
All experiments were performed in the presence of 0.5 M tetrodotoxin (TTX; Sigma-Aldrich) to minimize indirect effects. In addition, in a few experiments, the I h blocker ZD7288 (30 M; SigmaAldrich) and the SK channel blocker apamin (300 nM; SigmaAldrich) were used. Finally, the GABA A antagonist SR95531 (10 M; gift from Sanofi-Synthélabo, Paris, France) was also used in some experiments to exclude the possibility of an action of retigabine on these receptors (van Rijn and Willems-van, 2003) .
The KCNQ channel blocker XE991 was synthesized at the Department of Medicinal Chemistry (NeuroSearch A/S, Ballerup, Denmark), dissolved in DMSO (final concentration of DMSO 0.1%), and applied by superfusion using three-way taps. Complete exchange of the bath solution occurred within 2 to 3 min.
In Vivo Single-Unit Electrophysiology. Rats (n ϭ 8) were anesthetized with chloral hydrate (400 mg/kg i.p.) and mounted in a Kopf stereotaxic frame with the incisor bar set 3.75 mm below the interaural line. They were fitted with a catheter in the femoral vein to administer drugs (1.0 ml/kg) and supplementary anesthesia (80 mg/kg i.v.). Body temperature was monitored by a rectal thermometer and maintained at 36.5-37.0°C with a thermostatically controlled heating pad. An incision was made in the scalp, the skull was exposed, and a burr whole was drilled overlying the SN. The dura mater was retracted, and a glass microelectrode (filled with 2 M NaCl) was used to perform extracellular single-unit recordings from DA neurons in the SNc. Electrode penetrations were made through the SNc in the dorsoventral direction from 6.0 to 8.0 mm below the dura, 3.0 to 3.3 mm anterior to the interaural line, and 2.2 to 2.4 mm lateral to the midline, respectively, according to Paxinos and Watson (1986) . As reported previously, the DA neurons 1) exhibited a characteristic triphasic waveform with a long action potential of 2.5 to 3.5 ms; (2) had low spontaneous firing rates of 0.5 to 10 Hz, and an irregular firing pattern; and 3) were inhibited by apomorphine (0.04 mg/kg i.v.; Sigma-Aldrich) (Grace and Bunney, 1980) . Baseline activity of DA cells was recorded for at least 3 min before intravenous drug administration. Haloperidol (0.08 mg/kg i.v.; Janssen-Cilag, Beerse, Belgium) was administered following recovery of the spike frequency after apomorphine treatment. Upon haloperidol administration, DA cell firing was allowed to reach a stable plateau before administering retigabine (2.5 mg/kg i.v.) or vehicle (10% Tween 80 in 0.9% NaCl, i.v.). Firing rates were collected online via an interface (1401Plus, Cambridge Electronic Design) using the Spike2 software (Cambridge Electronic Design). The total number of spikes was calculated every 10 s. In all experiments, only one cell per animal was monitored unilaterally for its response to drug administration. Recordings were averaged over a total time interval of 3 min and compared with the baseline activity defined as the mean spike level before the first drug injection. The statistical significance of the effect of haloperidol and retigabine, respectively, was determined by comparing the activity of the cell measured as the averaged spike frequency within a time period of 3 min before drug administration and within 2 to 10 min after drug injection. The effect of drug exposure was analyzed using a one-way ANOVA followed by Tukey's post hoc test.
Immunohistochemical Analysis of c-Fos Expression. Rats were injected i.p. with a single dose of 10 mg/kg retigabine (dissolved in 10% Tween 80 in 0.9% NaCl; n ϭ 7) or vehicle (n ϭ 8). To examine the inhibitory role of retigabine, combinations of two drug substances or vehicle (n ϭ 6/group) were given to each rat. Within a 15-min interval, each animal was injected with 0.1 to 10 mg/kg retigabine (dissolved in 10% Tween 80 in 0.9% NaCl) or vehicle followed by i.p. administration of either saline vehicle, 1.0 mg/kg haloperidol (dissolved in 0.9% NaCl), or 0.5 mg/kg raclopride, dissolved in 0.9% NaCl; Sigma-Aldrich). XE991 (3.0 mg/kg; dissolved in 10% Tween 80 in 0.9% NaCl) or vehicle (n ϭ 6) was administrated 5 min before retigabine.
The animals were returned to their home cages, and 60 min after the injection of retigabine or corresponding vehicle they were deeply anesthetized with 50 mg/ml (3.0 ml/kg) mebumal (SAD, Copenhagen, Denmark) and perfused transcardially with PBS followed by 4% paraformaldehyde in 0.1 M phosphate buffer for 10 min. For c-Fos immunocytochemistry, the forebrains were immersed in fixative overnight and subsequently submerged in 30% sucrose in PBS at 4°C for 3 days. Forty-micrometer serial coronal sections were cut through the forebrain on a freezing microtome, and representative sections were processed immunocytochemically according to the avidin-biotin immunocytochemical protocol reported previously (Mikkelsen et al., 1998) . The primary polyclonal antiserum (1:4000), characterized previously (Mikkelsen et al., 1998) , was generated in rabbit against the N-terminal peptide similar to amino acids 2 to 17 of the rat c-Fos protein.
The number of c-Fos-positive cells was counted by means of light microscopy (20ϫ magnification) using a counting grid (500 ϫ 500 m) placed over the shell (ACCshell) and core (ACCcore) of nucleus accumbens as well as the dorsolateral part of the rostral striatum (STRdl). The number of c-Fos-positive cells was averaged from two adjacent sections of each animal, and statistical analysis was performed on group means Ϯ S.E.M. using an unpaired t test or one-way ANOVA with Tukey's post hoc test where appropriate.
Protein Analysis and Immunoblotting. To determine the influence on an effector of DA synthesis an assay detecting the Ser40 phosphorylation level of tyrosine hydroxylase was applied (Håkans-son et al., 2004) . In an initial experiment, rats (n ϭ 6/group) were injected with 1.0 mg/kg haloperidol and sacrificed at various times after the injection (15, 30, or 60 min). Because the maximal level of Ser40 phosphorylation of TH was observed 30 min post-treatment, this time was used to determine any inhibitory effect of retigabine. Retigabine (10 mg/kg i.p.) was administered 15 min before haloperidol (1.0 mg/kg i.p.). The rats were sacrificed 30 min after haloperidol treatment, and the left and right dorsolateral striatae were rapidly excised, pooled, and snap-frozen in liquid nitrogen, and kept at Ϫ80°C until further processing. For Western blotting analysis, total protein was extracted using the Total Protein extraction kit (Chemicon International, Temecula, CA), according to the manufacturer's instructions. The supernatant was collected and the protein concentration was determined using a modified Lowry method (DC Protein Assay kit; Bio-Rad, Hercules, CA). Protein extracts (20 g/sample) and a prestained weight marker (Invitrogen) were denatured in sample loading buffer (Invitrogen) under reducing conditions, separated by 10% SDS-polyacrylamide gel electrophoresis, and electro-transferred in transfer buffer (80 mM Tris-HCl. 39 mM glycine, and 20% methanol) to a nitrocellulose membrane (0.2-m pore, Protran; Whatman Schleicher and Schuell, Dassel, Germany). The membrane was rinsed with Tris-buffered saline solution with Tween 20 (10 mM Tris, 150 mM NaCl, and 0.1% Tween 20, pH 7.6) and treated with blocking solution (5% nonfat dry milk in Tris-buffered saline solution with Tween 20) for 2 h at room temperature to prevent nonspecific antibody binding. Equal loading and transfer of proteins were initially confirmed by staining the membrane with Ponceau-S solution (Fluka, Buchs, Switzerland). The membrane was incubated overnight at 4°C with a rabbit phospho-specific Ser40-tyrosine hydroxylase antibody (P-TH; 1:3000; Chemicon International) or TH (1:4000) (Chemicon International), respectively. Following incubation with anti-rabbit horseradish peroxidase-labeled secondary antibody (1: 30,000; GE Healthcare, Piscataway, NJ) at room temperature for 2 h, the immunoreactive protein was visualized by an enhanced chemiluminescence system (Pierce Chemical, Rockford, IL), and serial exposures were made on autoradiographic films (GE Healthcare). For control of loading and transfer efficacy, the membranes were stripped for 5 min at 37°C using a commercial stripping reagent (Restore Western Blot Stripping buffer; Pierce Chemical) and reprobed with a rabbit polyclonal actin antibody (1:30,000; SigmaAldrich). Densitometric analyses of blots were performed using Image-Pro 5.1 (Media Cybernetics, Inc., Silver Spring, MD), and data were expressed as P-TH or TH, respectively, relative to the corresponding actin level.
Microdialysis of Striatal Dopamine and Dopamine Metabolites in the Striatum. Each rat was anesthetized with isoflurane (1.5% isoflurane in a mixture of 20% O 2 and NO 2 ) and placed in a stereotaxic frame. The anesthesia was maintained, and the rectal temperature was continuously measured during the experiment. The CMA/12 microdialysis probe (CMA Microdialysis, Solna, Sweden) of 4 mm in length was placed unilaterally into striatum. The probe was placed at the following coordinates: anterior-posterior, ϩ 1.0 mm; lateral, 3.0 mm; and ventral, Ϫ6.0 mm (from the dura) (Paxinos and Watson, 1986) . The probe was perfused at a flow rate of 2 l/min with Ringer solution (147 mM NaCl, 4 mM KCl, and 2.3 mM CaCl 2 , pH 6.5) immediately after the implantation. The first three samples were discarded, and the subsequent three samples were collected to determine the baseline of extracellular DA and the DA metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). Thereafter, retigabine (10 mg/kg i.p.; n ϭ 6) or vehicle (10% Tween 80 in 0.9% NaCl; n ϭ 10) was administered, and the following samples (20 min each) were collected for a total of 180 min. The brain dialysates collected from the probe were used for separate analysis of DA, DOPAC, and HVA. Only rats with a verified correct placement of the probe in the striatum were included in the study.
Concentrations of DA, DOPAC, and HVA were determined by reversed-phase high-performance liquid chromatography with electrochemical detection as described previously (Weikop et al., 2004) . The mean area under the curve levels of DA, DOPAC, and HVA, respectively, were calculated from the three last microdialysate fractions collected before retigabine administration, normalized to 100%, and thus considered being the basal level. All subsequent DA, DOPAC, and HVA sample values are expressed as mean levels Ϯ S.E.M. relative to the basal levels. Statistical analysis was carried out using a two-way ANOVA (treatment ϫ time) with Bonferroni's post hoc test.
Results

Localization of KCNQ Subunits in the Ventral Tegmentum
We examined the anatomical, cellular, and subcellular localization of KCNQ subunits in the ventral mesencephalon using well characterized antisera. Immunoreactivity for the KCNQ channel subunits were observed to be differentially distributed in the SN as well as in other parts of the brain, as reported recently (Kharkovets et al., 2000; Cooper et al., 2001; Yus-Najera et al., 2003) . Only KCNQ2 and KCNQ4 immunoreactivity was detected in the SN (Fig. 1, A-D) . Bright-field microscopy revealed the presence of KCNQ2 immunoreactive neurons in both the SNc and SN pars reticulata (SNr) compartments; however, it was evident that more KCNQ2-immunopositive neurons were present in the SNr than in the SNc (Fig. 1A) . Relatively few KCNQ2-expressing neurons were found in the VTA (Fig. 1A) . KCNQ4-positive neurons were widely distributed in the SNc and the adjacent VTA with an extensive number of KCNQ4-positive neurons in both regions (Fig. 1C) . A few KCNQ4-positive neurons were present in the SNr (Fig. 1C) .
KCNQ4 immunoreactivity seemed to overlap with DA cellrich areas, i.e., in the SNc, the VTA and the overlying A8 cell group in the retrorubral area, but not in other parts of the ventral mesencephalon. Confocal immunofluorescence microscopy of sections costained for KCNQ4 and TH revealed that these two antigens completely overlapped in the SNc (Fig. 1, E-G) and VTA (data not shown). As indicated in Fig.  1F , the KCNQ4-labeled profile was observed not only in relation to plasma membranes but also was intracellular and in primary processes, whereas TH immunoreactivity was more homogenously distributed in the cytoplasm.
Effect of Retigabine and XE991 on Midbrain Dopamine Cell Firing in Vitro
Extracellular Recordings. Retigabine exhibited a potent and robust inhibitory action on neuronal firing of DA neurons in the SNc (Fig. 2A) . Thus, 1 M retigabine significantly inhibited basal spike frequency and a concentration of 10 M completely blocked neuronal firing ( Fig. 2A) . The IC 50 of retigabine was 2.1 Ϯ 0.4 M (n ϭ 10).
To determine the target specificity of retigabine, 1 M XE991 was added to the slice preparation under incrementing concentrations of retigabine. Application of retigabine in a concentration (10 M) that completely blocks spike activity when applied alone had no activity when coapplied with XE991 (Fig. 2B) . Only very high concentrations of retigabine could overcome the blockade by XE991 (Fig. 2B) . The IC 50 of retigabine in the presence of 1 M XE991 was 192 Ϯ 40 M (n ϭ 6). Thus, 1 M XE991 shifted the IC 50 value of retigabine 91-fold. XE991 inhibited retigabine at even lower concentrations, since at 100 nM, it still shifted the IC 50 value of retigabine significantly (6.2 Ϯ 1.2 M in control conditions versus 2.1 Ϯ 0.4 M; n ϭ 6; p ϭ 0.0072). Further quantitative analysis of the antagonism of retigabine by XE991, revealed that the "K B " value (in analogy with receptor pharmacology: the concentration that doubles the IC 50 of retigabine) of XE991 was 66 nM (Fig. 2C) . Interestingly, XE991 produced a modest, but significant, increase (22%) of spike frequency (p ϭ 0.007, t test; Fig. 2B ).
In the VTA, retigabine also displayed an inhibitory effect on the basal spike activity. The IC 50 of retigabine was 1.7 Ϯ 0.4 M (n ϭ 5; Fig. 2D ) and was not different from the IC 50 of retigabine in SNc slice preparations (p ϭ 0.53). The inhibitory effect of retigabine in the VTA was completely blocked by 1 M XE991 (n ϭ 2) (Fig. 2D) . D 2 receptor antagonists (haloperidol and raclopride at 1 M) had no significant influence on the basal DA neuron firing rate in rat midbrain slices, and they did not change the effect of retigabine when coapplied (data not shown).
Intracellular Recordings. For intracellular recordings, the effect of retigabine was assessed in five SNc DA neurons. In two neurons, the experiments were performed in the presence of TTX. In three other neurons, the GABA A antagonist SR95531, the I h blocker ZD7288, and the SK channel blocker apamin were also added to the control superfusion medium. Since no difference was observed between the two conditions, the results were pooled. The initial membrane potential was set at Ϫ50 mV by small DC current injections (ϩ20 to Ϫ70 pA). Retigabine (10 M) induced a hyperpolarization of 9.4 Ϯ 2.0 mV (Fig. 3A) (n ϭ 5) . When the membrane potential was brought back to its initial value by current injection, a 54% drop in input resistance was observed (226 Ϯ 46 -102 Ϯ 13 M⍀). As shown in Fig. 3A , this effect was maintained during the superfusion of the drug and was only slowly reversible after washout. These effects of retigabine were completely blocked by the simultaneous application of 10 M XE991 (n ϭ 3; Fig. 3B ). XE991 had very little effect on the membrane potential when it was applied alone (data not shown). At Ϫ80 mV, retigabine did not induce a hyperpolarization.
A final set of experiments was performed with XE991. At 10 M, the KCNQ channel blocker did not modify the action potential amplitude (59.2 Ϯ 2 mV in control condition versus 59.1 Ϯ 2 mV with XE991) or duration (0.97 Ϯ 0.1 ms in control condition versus 1.0 Ϯ 0.1 ms with XE991). In addition, 10 M XE991 did not induce significant changes in the membrane potential ( Fig. 4A ) and had no influence on the medium afterhyperpolarization (mAHP) phase displayed by DA neurons (Fig. 4B) , which is mediated by SK3 channels Fig. 3 . Effect of retigabine is due to an enhancement of a M-type current in DA neurons. A, retigabine induces a steady hyperpolarization and a decrease in input resistance in a DA neuron. Membrane potential and injected currents are shown. B, effect of retigabine is completely antagonized by XE991. XE991 had very little effect per se on the membrane potential (data not shown).
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at ASPET Journals on April 19, 2017 jpet.aspetjournals.org (Shepard and Bunney, 1991; Wolfart et al., 2001 ). However, 10 M XE991 induced an increase in the number of spikes produced by depolarizing pulses (Ն800 ms) in three of six SNc DA neurons (Fig. 4C) .
Effect of Retigabine on SNc Dopamine Cell Firing in Vivo
Single unit recordings were used to determine the effect of retigabine on SNc DA neuron firing in vivo. The neurons used for further characterization were selected if they displayed efficient firing inhibition by administration of the D 2 receptor agonist apomorphine and excitation following treatment with haloperidol due to acute D 2 receptor blockade (Fig. 5A) . Retigabine (2.5 mg/kg; n ϭ 8) almost instantly reduced the firing rate in SNc DA neurons from 160 Ϯ 19 spikes/10 s (after haloperidol treatment) to 28 Ϯ 13 spikes/10 s (after retigabine treatment), thus significantly reducing the enhanced spike activity induced by haloperidol (p Ͻ 0.0001). It is noteworthy that retigabine reduced the spike activity to a level below baseline (basal 84 Ϯ 6 spikes/10 s versus retigabine, 28 Ϯ 13 spikes/10 s; p ϭ 0.0022), even in the presence of haloperidol (Fig. 5, A and B) . The prominent inhibitory effect of retigabine on DA cell firing was sustained throughout the experiment, thus lasting more than 10 min (Fig. 5, A  and B) .
Retigabine Inhibits c-Fos Activation in the Striatum
Functional analysis of retigabine on striatal activity was performed using the immediate-early transcription factor cFos as a marker of postsynaptic neuronal excitation. The basal level of c-Fos expression (cells/millimeter 2 ) varied in different parts of the striatum, with the highest level in the ACCshell (199 Ϯ 35, Fig. 6E ) and lower in the ACCcore (70 Ϯ 26; Fig. 6I ) and STRdl (50 Ϯ 13; Fig. 6A ). Administration of retigabine alone produced a significant reduction in basal striatal c-Fos levels. Compared with basal levels in vehicletreated rats, 10 mg/kg retigabine reduced c-Fos levels to almost undetectable levels in the STRdl (6 Ϯ 4, p ϭ 0.0094; Fig. 6F ) and ACCcore (26 Ϯ 10; p ϭ 0.0211; Fig. 6J ), whereas basal c-Fos expression in the ACCshell (83 Ϯ 19; p ϭ 0.0153; Fig. 6B ) was partially blocked by retigabine.
As expected, haloperidol induced an intense c-Fos immunoreactivity in all parts of the striatum examined (Figs. 6 and 7), i.e., the dorsolateral region (15-fold increase), ACCshell (2-fold increase), and ACCcore (7-fold increase). Pretreatment with retigabine inhibited haloperidol-induced c-Fos dose dependently, being evident in all aspects of the striatum examined (Figs. 6 and 7) , because the inhibition was prominent in both the dorsal striatum (Fig. 6, A-D) as well as in ACCshell (Fig. 6 , E-H) and ACCcore (Fig. 6, I-L) , respectively. The lowest dose of retigabine in all segments of Fig. 4 . A, KCNQ channel blocker XE991 (10 M) does not modify the amplitude or duration (measured at mid-height) of action potentials recorded intracellularly in rat SNc DA neurons. B, 10 M XE991 has no influence on the mAHP phase displayed by SNc DA neurons. C, 10 M XE991 induces an increase in the number of spikes produced by depolarizing pulses in a fraction of SNc DA neurons. Action potentials elicited in two different DA neurons by 1.4-s depolarizing current injections of increasing amplitude before (traces 1 and 3) and during application of 10 M XE991 (traces 2 and 4). Membrane potential was set at Ϫ63 mV before drug application. XE991 did not have a significant effect on the baseline membrane potential. Note that XE991 increased the excitability of one cell (traces 1 and 2), whereas it did not modify the excitability of another cell (traces 3 and 4). In the ventral striatum, the haloperidol-activated neurons were organized in the characteristic patches (Fig. 6G) . It is noteworthy that retigabine eliminated the accumbal patchy organization of the c-Fos-immunopositive neurons (Fig. 6, H and L).
The inhibition of haloperidol-induced c-Fos levels in the striatum was counteracted by XE991 preadministration. In all striatal areas examined, the inhibitory effect of retigabine was reversed completely to a level indistinguishable from animals treated with haloperidol alone (Fig. 8, A-C) . When administered alone, XE991 had no effect on c-Fos expression in any striatal subregion examined (Fig. 8) .
The selective D 2 receptor antagonist raclopride produced a prominent induction of c-Fos in the striatum, topographically and quantitatively similar to that of haloperidol. The prominent stimulatory effect of raclopride in the ventral striatum was completely blocked by preadministration of retigabine (ACCshell: vehicle, 200 Ϯ 50; raclopride, 410 Ϯ 27; retigabine ϩ raclopride, 187 Ϯ 39; p Ͻ 0.001; ACCcore: vehicle, 80 Ϯ 45; raclopride, 347 Ϯ 72; retigabine ϩ raclopride, 70 Ϯ 19; p Ͻ 0.001), whereas the inhibitory effect of retigabine was only partial in the STRdl (vehicle, 6 Ϯ 3; raclopride, 802 Ϯ 129; retigabine ϩ raclopride, 255 Ϯ 106; p ϭ 0.0057). 
Retigabine Blocks Induction of TH Phosphorylation in the Striatum
Western blot analysis indicated that acute haloperidol treatment stimulated Ser40 phosphorylation of TH in tissue extracts of the STRdl. TH Ser40 phosphorylation was significantly increased 30 min after haloperidol administration (p ϭ 0.0012), whereas TH Ser40 phosphorylation slightly, but nonsignificantly, stimulated at 15 and 60 min after haloperidol administration (Fig. 9A) . The short-term effect of haloperidol on TH phosphorylation is in agreement with previous reports (Salvatore et al., 2000; Håkansson et al., 2004) . Hence, because of the clear time-dependent response on haloperidol-induced Ser40 phosphorylation, the effect of retigabine was monitored 30 min after haloperidol administration.
As illustrated in Fig. 9B , retigabine had no effect on Ser40 phosphorylation per se, but it completely reversed the stimulatory effect of haloperidol. Subsequent Western blot analysis of total TH levels using a phosphorylation-independent TH antibody indicated that neither haloperidol, retigabine, nor the retigabine-haloperidol combination had any effect on total TH levels compared with control levels (one-way ANOVA, p ϭ 0.598) (data not shown).
Retigabine Reduces Extracellular Levels of Dopamine Metabolites in Vivo
In vivo microdialysis was used to measure the effects of retigabine on the level of DA and the corresponding DA metabolites in the striatum (Fig. 10) . Administration of retigabine alone did not influence extracellular DA levels in the striatum (p ϭ 0.6638; Fig. 10A ). By contrast, the levels of the two principal DA metabolites DOPAC (Fig. 10B) and HVA (Fig. 10C) were significantly reduced during retigabine treatment (p Ͻ 0.0001 for both metabolites). The retigabine-induced inhibitory effect on DOPAC and HVA levels declined gradually. For DOPAC, the reduction was statistically significant at 60 min postinjection, whereas HVA levels were significantly decreased at 100 min, and the response on both DA metabolites continued to decline throughout the experiment. 
KCNQ Channels Modulate Dopaminergic Neurotransmission Discussion
Here, we demonstrate that retigabine profoundly affects neuronal excitability in SNc DA neurons. In vitro, the effect of retigabine was both robust and highly sensitive to the KCNQ channel blocker XE991, indicating that retigabine acted via activation of KCNQ channels. A similar and equipotent effect of retigabine was also observed in the VTA. Our intracellular recordings performed in the presence of TTX and during blockade of GABA A receptors, SK channels, and I h channels exclude the possibility that the inhibitory effect of retigabine on the excitability of DA neurons is mediated by an indirect effect in the SNc or by another action of retigabine. The lack of effect at Ϫ80 mV is consistent with an action on an M-type current (Delmas and Brown, 2005) .
In vivo, the single unit recordings confirmed the in vitro observations by showing that retigabine not only fully blocked haloperidol-induced increase in firing rate but also efficiently reduced the basal firing activity of SNc DA neurons. A XE991-sensitive, typical M-type current has recently been demonstrated in dissociated VTA DA neurons (Koyama and Appel, 2006) . Together, those voltage-clamp experiments and our extracellular (both in vitro and in vivo) and intracellular recordings demonstrate the existence of a retigabineand XE991-sensitive M-current in mesencephalic DA neurons. Our experiments further demonstrate that this current can be potentiated by retigabine under physiological conditions.
XE991 alone had very little effect on the membrane potential of SNc DA neurons, and it did not affect the mAHP. However, XE991 increased the excitability of a fraction of SNc DA neurons, an effect similar to that reported for VTA DA neurons (Koyama and Appel, 2006) . These observations suggests that KCNQ channels sustaining this current may be differently expressed among DA neurons, either in terms of channel density, subunit composition, or subcellular distribution.
Because KCNQ-immunopositive neurons were found in the SN and VTA, the powerful effect of retigabine is most likely triggered locally within the ventral tegmentum. The SN and VTA neurons displayed subunit-restricted KCNQ-labeling, because only immunoreactivity for KCNQ2 and KCNQ4 was found. In addition, the IC 50 for tetraethylammonium measured in dissociated VTA DA neurons is reported to lie between the IC 50 of KCNQ2 and KCNQ4 channels, whereas the IC 50 of XE991 is closest to that of expressed KCNQ2 channels (Koyama and Appel, 2006) . This is interesting, because KCNQ2 and KCNQ4 do not coassemble in vitro to generate functional heteromeric channels (Kubisch et al., 1999) . The lack of KCNQ3 immunoreactivity likely rules out that KCNQ2 and KCNQ4 immunoreactivity in the ventral tegmentum represents heteromeric KCNQ channels, and they may therefore operate as homomers. In accordance, homomeric KCNQ2 and KCNQ4 channels are capable of generating potassium currents in vitro (Biervert et al., 1998; Kubisch et al., 1999) . KCNQ2 immunoreactivity was present throughout the SN, as also reported in the mouse (Cooper et al., 2001 ). In contrast, KCNQ4 subunits were observed in the rat SNc, but not in the SNr. The KCNQ4 subunit was predominantly localized to the plasma membrane; however, KCNQ4 immunoreactivity was also observed in intracellular and primary processes, in agreement with Kharkovets et al. (2000) . Presumably, these KCNQ4 channel proteins are retained as a consequence of incomplete trafficking to the plasma membrane, or, alternatively, they may be destined for trafficking to axonal, dendritic, or perisynaptic sites, as suggested for KCNQ2 channels (Cooper et al., 2001) .
This restricted subregional localization of KCNQ4 subunits is in agreement with a report on murine KCNQ4 distribution (Kharkovets et al., 2000) . In the SNc and VTA, KCNQ2 channels were much less expressed than KCNQ4 channels, likely indicating that the KCNQ4 channel is the predominant KCNQ channel responsible for the strong inhibitory effect of retigabine on DA neurotransmission. This is Fig. 9 . Hal (1.0 mg/kg i.p.) stimulates Ser40 phosphorylation of TH (P-TH) in the dorsolateral striatum of rats. The effect was time-dependent with a significant increase at 30 min ‫,ءء(‬ p Ͻ 0.01) (A). Ret (10 mg/kg i.p.) completely blocked the haloperidol-induced (1.0 mg/kg i.p.) phosphorylation of TH ‫,ءءء(‬ p Ͻ 0.01 versus haloperidol) (B). The inhibitory effect of retigabine on haloperidol-induced P-TH was phosphorylation-specific, because retigabine did not influence total TH protein levels in the STRdl (data not shown). further supported by the immunohistochemical analysis of the principal neuronal phenotype expressing KCNQ4 subunits in the SNc and VTA, revealing that all KCNQ4 channels were present on TH-positive neurons and that KCNQ4 immunoreactivity was extensive, because virtually all mesencephalic DA neurons expressed KCNQ4 channels. We therefore conclude that the mesencephalic homomeric KCNQ4 channel is the molecular target of retigabine leading to inhibition of DA neuron firing.
The strong inhibitory effect of retigabine on mesencephalic DA activity is intriguing. Since the SNc and the lateral VTA provide essential and extensive DA modulatory inputs to striatal and mesolimbic targets (Swanson, 1982) , this suggests that KCNQ channel modulation occurs in both nigrostriatal and limbic pathways. Accordingly, retigabine almost completely eliminated basal excitability in both the dorsolateral and ventral aspects of the striatum, as inferred by the reduced levels of basal c-Fos immunoreactivity, a transcriptional marker commonly used to map changes in synaptic neuronal activity (Morgan and Curran, 1991) .
In addition, retigabine reduced basal striatal DOPAC and HVA without affecting DA levels. Since metabolism of DA, by concerted action of monoamine-oxidase and catechol-O-methyltransferase, results in DOPAC and HVA production, changes in DA metabolite levels reflect altered DA synthesis rate and DA neuronal activity (Di Giulio et al., 1978; Nissbrandt et al., 1989) , and we can therefore conclude that retigabine reduced DA synthesis in striatal nerve terminals. In accordance, retigabine also reversed haloperidol-induced TH Ser40 phosphorylation, a presynaptic marker of stimulated striatal DA synthesis (Håkansson et al., 2004) , indicating that retigabine was also capable of normalizing striatal TH activity in conditions of stimulated DA activity.
Acute blockade of DA D 2 receptors effectively depolarizes SNc neurons in vivo (Bunney et al., 1973 ) and leads to prominent striatal excitation by stimulating DA release (Di Chiara and Imperato, 1988), turnover (Zetterström et al., 1986) , and synthesis (Magnusson et al., 1987) . Haloperidol caused a pronounced c-Fos induction in the ventral and lateral striatum, interpreted as enhanced neuronal activity caused by acute blockade of somatodendritic and terminal DA D 2 receptor function . Retigabine eliminated the strong excitatory response to haloperidol, with an ED 50 of approximately 1 mg/kg, and also inhibited the effect of raclopride, emphasizing the inhibitory effect of retigabine on D 2 receptor blockade-mediated excitation. The potency of retigabine is higher than found in behavioral studies, where minimum effective doses typically range from 3 to 10 mg/kg (Korsgaard et al., 2005) . The negative modulatory effect on haloperidol-induced c-Fos was KCNQ-specific, because XE991 completely reversed this effect. Because virtually all DA neurons in the SNc and VTA express D 2 receptors (Khan et al., 1998) , this may be of functional relevance to KCNQ channel physiology. The interaction with the D 2 receptor-mediated c-Fos response in the striatum is further emphasized by the observation that flupirtine inhibits haloperidol-induced catalepsy, which is a typical extrapyramidal effect of generalized D 2 receptor blockade (Schmidt et al., 1997) . Furthermore, motor impairment is also observed in rats exposed to acute retigabine administration (Rostock et al., 1996; Korsgaard et al., 2005) , which may thus directly relate to the potent inhibitory effect of retigabine on striatal excitability. Although the functional consequences of systemic administration of retigabine likely occur in the SNc and VTA, the striatal effect could potentially also be explained by actions independent on DA input from the SNc and VTA.
Striatal neurons express KCNQ2, KCNQ3, and KCNQ5 but not KCNQ4 channels (Cooper et al., 2001; Shen et al., 2005) . In addition, heteromeric KCNQ2/3 channels are suggested to provide inhibitory tonus on striatopallidal/striatonigral neurons (Shen et al., 2005) . Striatopallidal neurons express D 2 receptors (Gerfen et al., 1990 ) and respond to excitatory D 2 receptor blockade (Robertson and Jian, 1995) . Thus, retigabine may also affect neuronal excitability by direct action on striatopallidal neurons. However, because striatal c-Fos induction by pharmacological D 2 receptor blockade is critically dependent on mesolimbic DA inputs , this likely rules out that intrastriatal KCNQ channels contributed significantly to the inhibitory effect of retigabine. In addition, the cortex and corticostriatal projections express KCNQ channel subunits (Cooper et al., 2001; Yus-Najera et al., 2003) , which tentatively suggests that KCNQ channels on corticostriatal projections may play a role in the control of striatal excitability.
In conclusion, the prominent inhibitory effect of KCNQ channel activation in nigrostriatal and mesolimbic pathways suggests that pharmacological enhancement of KCNQ channel function may be a novel approach to improve conditions of DA overactivity in the basal ganglia. Consistent with the localization of KCNQ4 subunits on key sites for control of cerebral DA activity, homomeric KCNQ4 channels may represent a novel target for treating disease states characterized by abnormal DA neurotransmission, e.g., schizophrenia, attention deficit hyperactivity disorder, and drug abuse.
